65
Participants
Start Date
June 10, 2022
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
Atezolizumab
Given PO
Bevacizumab
Given IV
Biopsy Procedure
Undergo biopsy
Biospecimen Collection
Undergo blood collection
Bone Scan
Undergo bone scan
Computed Tomography
Undergo CT without contrast
Computed Tomography with Contrast
Undergo CT with contrast
Erlotinib
Given PO
Magnetic Resonance Imaging
Undergo MRI
Positron Emission Tomography
Undergo PET
Sodium Fluoride F-18
Given F-18 sodium fluoride
ACTIVE_NOT_RECRUITING
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
ACTIVE_NOT_RECRUITING
NYU Langone Hospital - Long Island, Mineola
RECRUITING
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
SUSPENDED
National Institutes of Health Clinical Center, Bethesda
RECRUITING
NCI - Center for Cancer Research, Bethesda
RECRUITING
Emory University Hospital Midtown, Atlanta
RECRUITING
Emory University Hospital/Winship Cancer Institute, Atlanta
RECRUITING
Emory Saint Joseph's Hospital, Atlanta
RECRUITING
Ohio State University Comprehensive Cancer Center, Columbus
RECRUITING
Northwestern University, Chicago
RECRUITING
M D Anderson Cancer Center, Houston
RECRUITING
UC San Diego Moores Cancer Center, La Jolla
SUSPENDED
Rutgers Cancer Institute of New Jersey, New Brunswick
National Cancer Institute (NCI)
NIH